Genprex is a clinical-stage gene therapy company that is dedicated to developing life-changing therapies for patients with cancer and diabetes. With a focus on innovative science, Genprex aims to deliver gene therapies that provide new treatment options for large patient populations with limited options. Genprex collaborates with world-class institutions and partners to develop drug candidates and expand its pipeline of gene therapies.

The company's oncology program utilizes the ONCOPREX® Nanoparticle Delivery System, a groundbreaking non-viral gene therapy platform used for cancer treatment in humans. This system encapsulates gene-expressing plasmids using lipid nanoparticles, allowing for intravenous administration and specific targeting of tumor cells. Genprex's lead product candidate, REQORSA™, is undergoing evaluation as a treatment for non-small cell lung cancer and small cell lung cancer, with Fast Track Designation from the FDA.

Additionally, Genprex is exploring a novel gene therapy approach for diabetes, utilizing an infusion process with an adeno-associated virus to deliver specific genes to the pancreas. Committed to excellence and integrity, Genprex is dedicated to transforming the lives of patients affected by cancer and diabetes. The company's multidisciplinary team of professionals brings together expertise from the biotech and pharmaceutical industries, as well as leading medical and academic institutions worldwide.

Join Genprex in their mission to revolutionize gene therapy and make a difference in the lives of patients